A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

NCT03126591 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Soft Tissue Sarcoma

Interventions

DRUG: Olaratumab
DRUG: Pembrolizumab (KEYTRUDA®)

Sponsor

Eli Lilly and Company

Collaborators

[object Object]